NasdaqGS - Nasdaq Real Time Price • USD
Novavax, Inc. (NVAX)
As of 2:53 PM EDT. Market Open.
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 5 | 5 | 6 | 6 |
| Avg. Estimate | -1.06 | -0.85 | -0.72 | -0.04 |
| Low Estimate | -1.48 | -1.23 | -1.59 | -1.23 |
| High Estimate | -0.85 | -0.53 | 0.13 | 1.66 |
| Year Ago EPS | -3.41 | 0.58 | -5.41 | -0.72 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 5 | 5 | 6 | 6 |
| Avg. Estimate | 101.16M | 71.32M | 845.49M | 986.48M |
| Low Estimate | 99.8M | -- | 775M | 635M |
| High Estimate | 104M | 152M | 941.8M | 1.61B |
| Year Ago Sales | 80.95M | -- | 983.71M | 845.49M |
| Sales Growth (year/est) | 25.00% | -- | -14.10% | 16.70% |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | -3.46 | -1.39 | -1.83 | -0.45 |
| EPS Actual | -3.41 | 0.58 | -1.26 | -1.44 |
| Difference | 0.05 | 1.97 | 0.57 | -0.99 |
| Surprise % | 1.40% | 141.70% | 31.10% | -220.00% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -1.06 | -0.85 | -0.72 | -0.04 |
| 7 Days Ago | -0.92 | -1 | -0.73 | -0.05 |
| 30 Days Ago | -0.95 | -1.03 | -0.8 | 0.12 |
| 60 Days Ago | -0.05 | -1.54 | -0.3 | 0.06 |
| 90 Days Ago | -0.34 | -1.76 | -0.72 | -0.33 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | 1 | 1 | 1 |
| Up Last 30 Days | 1 | 2 | 2 | 1 |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | 1 | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | NVAX | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 68.90% | -- | -- | 1.50% |
| Next Qtr. | -246.60% | -- | -- | 11.40% |
| Current Year | 86.70% | -- | -- | 5.20% |
| Next Year | 94.40% | -- | -- | 13.40% |
| Next 5 Years (per annum) | -69.60% | -- | -- | 11.09% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Maintains | HC Wainwright & Co.: Buy to Buy | 3/1/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 8/10/2023 |
| Upgrade | B. Riley Securities: Neutral to Buy | 8/9/2023 |
| Reiterates | HC Wainwright & Co.: Buy | 5/10/2023 |
| Downgrade | B. Riley Securities: Buy to Neutral | 3/1/2023 |
| Reiterates | HC Wainwright & Co.: Buy | 2/13/2023 |
Related Tickers
MRNA Moderna, Inc.
105.70
-2.89%
IOVA Iovance Biotherapeutics, Inc.
11.56
-1.28%
INO Inovio Pharmaceuticals, Inc.
10.05
-1.08%
VXRT Vaxart, Inc.
0.6798
-4.21%
BNTX BioNTech SE
86.70
-1.58%
OCGN Ocugen, Inc.
1.2150
+2.98%
IBRX ImmunityBio, Inc.
5.11
+5.91%
BLUE bluebird bio, Inc.
0.9105
-1.34%
SAVA Cassava Sciences, Inc.
21.52
+3.76%
VKTX Viking Therapeutics, Inc.
67.15
+3.20%